Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-04

FDA Approved: SOVALDI — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Sovaldi (sofosbuvir) submitted by Gilead Sciences, Inc., resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sovaldi (Sofosbuvir)

Snippet

SUPPL AP for SOVALDI (SOFOSBUVIR)